Seeking Alpha

Actavis to launch generic Celebrex

  • Actavis (ACT) confirms that it will launch its generic Celebrex product in May after yesterday's favorable court ruling invalidating Pfizer's (PFE) patent.
  • The FDA must approval its Abbreviated New Drug Application before commercialization commences.
  • Celebrex generated $2.2B in US sales last year.
Comments (6)
  • racman27
    , contributor
    Comment (1) | Send Message
     
    A big plus for ACT, YES or No? I say Yes. How about you? But is it worth buying more?
    13 Mar, 08:24 AM Reply Like
  • bill d
    , contributor
    Comments (1899) | Send Message
     
    No. Too expensive. No dividend. And PFE beats it in all points and they can be very aggressive with competition.
    13 Mar, 03:24 PM Reply Like
  • fox dad
    , contributor
    Comments (5) | Send Message
     
    Thats a big market to get a piece of 2 billion !
    13 Mar, 04:02 PM Reply Like
  • fox dad
    , contributor
    Comments (5) | Send Message
     
    Thats a big market to get a piece of 2 billion !
    13 Mar, 04:02 PM Reply Like
  • fox dad
    , contributor
    Comments (5) | Send Message
     
    Bill d You can't compare act with pfe.,but pfe could buy act .
    14 Mar, 11:23 AM Reply Like
  • bill d
    , contributor
    Comments (1899) | Send Message
     
    MYL would be the better play than ACT.
    15 Mar, 02:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|